Moderna (MRNA) skyrocketed to fame during the pandemic. Its Covid-19 vaccine put the biotech on the map, sent sales soaring, and made the company one of Wall Street’s hottest names. Then the pandemic boom ran out of steam. Vaccine demand cooled, revenues took a hit, and the stock spent years trying to find its footing.
Fast-forward to 2026; the shares have soared roughly sixfold in 2026 alone, fueled by excitement around its personalized cancer vaccine developed with Merck (MRK). The rally accelerated after positive Phase 3 melanoma results, sending MRNA stock sharply higher as investors began pricing in a much bigger oncology opportunity.